DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma makes and distributes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis – with future targets for further and new patient groups and segments.

Quotes for DanCann Pharma A/S

Right Now

+/-
-0.05
%
-1,31%
Latest
3.755
High
3.78
Low
3.63
Volume
5 870
Turnover (DKK)
21 409
Value (MDKK)
84,2

Board

CEO

  • Jeppe Krog Rasmussen

Chairperson of the Board

  • Carsten Trads

Board

  • Carsten Trads
  • Jeppe Krog Rasmussen
  • Magnus Østergaard Dahlmann
  • Per Wester

Largest Owners

Name Capital % Votes % Date
Jeppe Krog Rasmussen 25,62 25,62 2021-07-26
Alexander Schoeneck 8,40 8,40 2021-08-19
Sellers of CannGros ApS 7,85 7,85 2021-10-05
Futur Pension 6,01 6,01 2020-11-12
Morten Martinsen 1,78 1,78 2021-08-19
Hansen & Nytoft Invest Aps 1,34 1,34 2021-08-19
Vavi Invest Aps 0,88 0,88 2021-08-19
John Frellsen 0,60 0,60 2021-07-26
JBJensen ApS 0,53 0,53 2021-08-19
Per Wester 0,50 0,50 2021-08-19
Holdings by Modular Finance AB. Compiled and processed data from various sources, including VP Securities, Morningstar and The Danish Financial Supervisory Authority (Finanstilsynet)

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2021-11-26 Delårsrapport 2021-Q3

  • 2022-02-25 Bokslutskommuniké 2021